产品说明书
Valacyclovir hydrochloride
 |
同义名 : | 盐酸伐昔洛韦 ;Valaciclovir hydrochloride;L-Valacyclovir (hydrochloride);BW 256U87;BW 256U;Valaciclovir HCl |
| CAS号 : | 124832-27-5 | |
| 货号 : | A199102 | |
| 分子式 : | C13H21ClN6O4 | |
| 纯度 : | 97% | |
| 分子量 : | 360.797 | |
| MDL号 : | MFCD11114398 | |
| 存储条件： |
粉末 Keep in dark place,Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 45 mg/mL(124.72 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 100 mg/mL(277.16 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
PO 0.5% CMC-Na 50 mg/mL suspension |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Valacyclovir Hydrochloride is the hydrochloride salt of valacyclovir. Valacyclovir is an acyclovir prodrug that, after metabolization, inhibits viral DNA replication. It is used in the management of herpes simplex and varicella zoster infections, as well as prophylactically for human cytomegalovirus infections[3]. Valacyclovir is safe and effective in the therapy of patients with herpes simplex and herpes zoster and may be useful in other viral infections[4]. Valacyclovir has similar efficacy to acyclovir in the episodic and suppressive treatment of genital herpes. In addition, valacyclovir is also indicated in the reduction of the sexual transmission of herpes simplex virus infection and for the treatment of herpes labialis. In herpes zoster, valacyclovir is more effective than acyclovir or placebo (and as equally effective as famciclovir) in shortening the length and severity of herpes zoster-associated pain and postherpetic neuralgia. Valacyclovir has an acceptable safety profile in patients with herpes simplex and herpes zoster[5]. Nucleoside analogues against herpes simplex virus (HSV) have been shown to suppress shedding of HSV type 2 (HSV-2) on genital mucosal surfaces and may prevent sexual transmission of HSV. Once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmission of genital herpes among heterosexual, HSV-2-discordant couples[6]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00946556 | Herpes Simplex Type Two Infect... 展开 >>ion HIV Infections 收起 << | Not Applicable | Completed | - | Canada, Ontario ... 展开 >> Women's Health In Women's Hands Toronto, Ontario, Canada 收起 << |
| NCT03131037 | Lung Cancer | Phase 1 | Recruiting | May 2022 | United States, Pennsylvania ... 展开 >> University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Brenda Horn 215-590-4202 brenda.horn@uphs.upenn.edu Principal Investigator: Sunil Singhal 收起 << |
| NCT01997190 | Malignant Pleural Effusion ... 展开 >> Lung Cancer Mesothelioma Breast Cancer Ovarian Cancer 收起 << | Phase 1 | Active, not recruiting | October 2020 | United States, Pennsylvania ... 展开 >> University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.77mL 0.55mL 0.28mL |
13.86mL 2.77mL 1.39mL |
27.72mL 5.54mL 2.77mL |
| 参考文献 |
|---|
|
[3]Biernat-Sudolska M. Valaciclovir [Valacyclovir]. Przegl Lek. 1998;55(11):596-8. Polish |